Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:IMRX NASDAQ:RNAC NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.65-2.9%$1.71$1.10▼$3.89$62.73M-0.8710,670 shs17,029 shsIMRXImmuneering$6.13-1.8%$5.94$1.10▼$10.08$259.40M0.473.49 million shs1.85 million shsRNACCartesian Therapeutics$9.32-7.7%$10.39$8.46▼$26.50$262.62M0.3987,052 shs73,042 shsTLSATiziana Life Sciences$2.04-4.2%$1.95$0.63▼$2.60$248.89M-0.37466,932 shs611,108 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-2.94%-4.07%-6.78%+2.52%-14.34%IMRXImmuneering-1.76%+1.32%-24.69%+38.69%+179.91%RNACCartesian Therapeutics-7.72%-8.54%-4.99%-30.03%-58.06%TLSATiziana Life Sciences-4.23%+3.55%+17.24%+37.84%+114.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.65-2.9%$1.71$1.10▼$3.89$62.73M-0.8710,670 shs17,029 shsIMRXImmuneering$6.13-1.8%$5.94$1.10▼$10.08$259.40M0.473.49 million shs1.85 million shsRNACCartesian Therapeutics$9.32-7.7%$10.39$8.46▼$26.50$262.62M0.3987,052 shs73,042 shsTLSATiziana Life Sciences$2.04-4.2%$1.95$0.63▼$2.60$248.89M-0.37466,932 shs611,108 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-2.94%-4.07%-6.78%+2.52%-14.34%IMRXImmuneering-1.76%+1.32%-24.69%+38.69%+179.91%RNACCartesian Therapeutics-7.72%-8.54%-4.99%-30.03%-58.06%TLSATiziana Life Sciences-4.23%+3.55%+17.24%+37.84%+114.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 1.50Reduce$9.00445.45% UpsideIMRXImmuneering 2.43Hold$16.40167.54% UpsideRNACCartesian Therapeutics 2.50Moderate Buy$40.00329.18% UpsideTLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ANL, IMRX, TLSA, and RNAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ANLAdlai NortyeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025IMRXImmuneeringWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RNACCartesian TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TLSATiziana Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/30/2025IMRXImmuneeringHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.009/27/2025ANLAdlai NortyeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (E+)9/27/2025IMRXImmuneeringWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RNACCartesian TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TLSATiziana Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.009/25/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $30.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M12.18N/AN/A$0.69 per share2.39IMRXImmuneering$320K796.33N/AN/A$1.33 per share4.61RNACCartesian Therapeutics$38.91M6.23N/AN/A($0.27) per share-34.52TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/AN/AIMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)RNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/AN/AN/A-6.36%11/6/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A10/13/2025 (Estimated)Latest ANL, IMRX, TLSA, and RNAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025N/ARNACCartesian Therapeutics-$0.81N/AN/AN/AN/AN/A8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/7/2025Q2 2025RNACCartesian Therapeutics-$0.76$0.50+$1.26$0.50$0.77 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/AN/AN/AIMRXImmuneeringN/A3.703.70RNACCartesian TherapeuticsN/A13.3313.33TLSATiziana Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%IMRXImmuneering67.65%RNACCartesian Therapeutics86.95%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AIMRXImmuneering22.90%RNACCartesian Therapeutics60.30%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableIMRXImmuneering6041.57 million32.05 millionNot OptionableRNACCartesian Therapeutics6426.00 million10.32 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableANL, IMRX, TLSA, and RNAC HeadlinesRecent News About These CompaniesWeiss Ratings Reiterates "Sell (D-)" Rating for Tiziana Life Sciences (NASDAQ:TLSA)October 9 at 12:36 AM | marketbeat.comTiziana Life Sciences to showcase drug candidate at Saudi innovation forumSeptember 30, 2025 | proactiveinvestors.comTiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi ArabiaSeptember 30, 2025 | globenewswire.comTiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.5% - Should You Sell?September 26, 2025 | marketbeat.comTiziana Life Sciences Stock Rises On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’September 25, 2025 | msn.comTiziana Life Sciences stock higher on inflammatory therapy plansSeptember 25, 2025 | proactiveinvestors.comTiziana to push ahead with second drug candidate in inflammation researchSeptember 25, 2025 | proactiveinvestors.comTiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal AntibodySeptember 25, 2025 | tmcnet.comTiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord InjurySeptember 25, 2025 | finance.yahoo.comTiziana to share trial design for nasal MS drug at global congressSeptember 24, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS CongressSeptember 24, 2025 | globenewswire.comTiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord InjurySeptember 23, 2025 | insidermonkey.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Increase in Short InterestSeptember 19, 2025 | marketbeat.comTiziana Life Sciences announces U.S. DoD awarded research grant to study SCISeptember 15, 2025 | msn.comTiziana Life Sciences Secures DoD Grant for Spinal Cord Injury ResearchSeptember 15, 2025 | msn.comTiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injurySeptember 15, 2025 | proactiveinvestors.comDepartment of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord InjurySeptember 15, 2025 | globenewswire.comTiziana Life Sciences reports CEO purchased 14,848 sharesSeptember 10, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by ChairmanSeptember 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANL, IMRX, TLSA, and RNAC Company DescriptionsAdlai Nortye NASDAQ:ANL$1.65 -0.05 (-2.94%) As of 10/10/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Immuneering NASDAQ:IMRX$6.13 -0.11 (-1.76%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$6.10 -0.04 (-0.57%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$9.32 -0.78 (-7.72%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$9.32 +0.00 (+0.05%) As of 10/10/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Tiziana Life Sciences NASDAQ:TLSA$2.04 -0.09 (-4.23%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$2.03 -0.01 (-0.49%) As of 10/10/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
